The top analyst upgrades, downgrades and other research calls from Monday include ADP, Bluebird Bio, DaVita, First Solar, Square, SunPower and US.. Steel.
Insider activity was limited last week, with windows for transactions being mostly closed, but we did see some huge institutional trades hit the tape.
2016 was hard for biotech stocks, some more than others. These three present a buy low opportunity.
At this point, bad news is coming in consistently to the point that any significant piece of good news could catapult Sanofi stock higher, making it an interesting choice for dip-buyers.
Here are three biotechs that just recently announced successful Phase 2 trial data for drugs with very big addressable markets.
Diabetes is becoming an epidemic in the U.S. and the Western World.  The ties to obesity are often direct, so the potential treatments are often directly tied as well.  We did a recent dig down for...